has Reason 5 O O
received Reason 5 O O
a Reason 5 O O
funding Reason 5 O O
grant Reason 5 O O
from Reason 5 O O
CARB-X Reason 5 O O
to Reason 5 O O
support Reason 5 O O
the Reason 5 O O
development Reason 5 O O
of Reason 5 O O
a Reason 5 O O
prophylactic, Reason 5 O O
multivalent Reason 5 O O
vaccine Reason 5 O O
against Reason 5 O O
carbapenem-resistant Reason 5 O O
Klebsiella Reason 5 O O
pneumoniae Reason 5 O O
(crKP). Reason 5 O O
The Reason 5 O O
initial Reason 5 O O
grant Reason 5 O O
of Reason 5 O O
up Reason 5 O O
to Reason 5 O O
$1.4m Reason 5 O O
may Reason 5 O O
expand Reason 5 O O
to Reason 5 O O
an Reason 5 O O
additional Reason 5 O O
$3.1m Reason 5 O O
contingent Reason 5 O O
upon Reason 5 O O
set Reason 5 O O
milestones. Reason 5 O O
Vaxxilon Reason 5 O O
plans Reason 5 O O
to Reason 5 O O
use Reason 5 O O
the Reason 5 O O
funds Reason 5 O O
for Reason 5 O O
preclinical Reason 5 O O
development, Reason 5 O O
GMP Reason 5 O O
manufacturing Reason 5 O O
and Reason 5 O O
a Reason 5 O O
Phase Reason 5 O O
I Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
of Reason 5 O O
VXN-319, Reason 5 O O
a Reason 5 O O
semi-synthetic Reason 5 O O
carbohydrate-based Reason 5 O O
conjugate Reason 5 O O
vaccine. Reason 5 O O
The Reason 5 O O
company Reason 5 O O
makes Reason 5 O O
carbohydrates Reason 5 O O
that Reason 5 O O
are Reason 5 O O
similar Reason 5 O O
to Reason 5 O O
the Reason 5 O O
sugar Reason 5 O O
coating Reason 5 O O
that Reason 5 O O
surrounds Reason 5 O O
each Reason 5 O O
bacterial Reason 5 O O
cell. Reason 5 O O
These Reason 5 O O
synthetic Reason 5 O O
carbohydrates Reason 5 O O
are Reason 5 O O
combined Reason 5 O O
with Reason 5 O O
additional Reason 5 O O
components Reason 5 O O
to Reason 5 O O
produce Reason 5 O O
conjugate Reason 5 O O
vaccines. Reason 5 O O
Currently, Reason 5 O O
VXN-319 Reason 5 O O
is Reason 5 O O
in Reason 5 O O
the Reason 5 O O
lead Reason 5 O O
optimisation Reason 5 O O
stage. Reason 5 O O
The Reason 5 O O
company Reason 5 O O
expects Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
to Reason 5 O O
protect Reason 5 O O
from Reason 5 O O
more Reason 5 O O
than Reason 5 O O
80% Reason 5 O O
of Reason 5 O O
strains Reason 5 O O
that Reason 5 O O
are Reason 5 O O
resistant Reason 5 O O
to Reason 5 O O
the Reason 5 O O
carbapenem Reason 5 O O
antibiotics. Reason 5 O O
Vaxxilon Reason 5 O O
CEO Reason 5 O O
Tom Reason 5 O O
Monroe Reason 5 O O
said: Reason 5 O O
"Carbapenem-resistant Reason 5 O O
Klebsiella Reason 5 O O
pneumoniae Reason 5 O O
is Reason 5 O O
spreading Reason 5 O O
quickly Reason 5 O O
around Reason 5 O O
the Reason 5 O O
world Reason 5 O O
and Reason 5 O O
Vaxxilon's Reason 5 O O
novel Reason 5 O O
vaccine, Reason 5 O O
if Reason 5 O O
approved, Reason 5 O O
could Reason 5 O O
prevent Reason 5 O O
infections, Reason 5 O O
save Reason 5 O O
lives Reason 5 O O
and Reason 5 O O
reduce Reason 5 O O
the Reason 5 O O
pressure Reason 5 O O
for Reason 5 O O
use Reason 5 O O
of Reason 5 O O
powerful Reason 5 O O
antibiotics. Reason 5 O O
"Carbapenems Reason 5 O O
are Reason 5 O O
a Reason 5 O O
powerful Reason 5 O O
class Reason 5 O O
of Reason 5 O O
antibiotics Reason 5 O O
and Reason 5 O O
when Reason 5 O O
those Reason 5 O O
treatments Reason 5 O O
are Reason 5 O O
ineffective Reason 5 O O
in Reason 5 O O
patients, Reason 5 O O
the Reason 5 O O
infections Reason 5 O O
become Reason 5 O O
very Reason 5 O O
difficult Reason 5 O O
to Reason 5 O O
treat." Reason 5 O O
[Klebsiella O O O O
pneumoniae](https://www.globaldata.com/store/report/klebsiella-pneumoniae-infections-drugs-in-development-analysis/) O O O O
are O O O O
known O O O O
to O O O O
be O O O O
responsible O O O O
for O O O O
severe O O O O
infections, O O O O
mainly O O O O
in O O O O
hospitals. O O O O
Several O O O O
strains O O O O
of O O O O
the O O O O
gram-negative O O O O
bacteria O O O O
have O O O O
already O O O O
become O O O O
resistant O O O O
to O O O O
antibiotics. O O O O
CARB-X O O O O
executive O O O O
director O O O O
Kevin O O O O
Outterson O O O O
said: O O O O
"Vaxxilon's O O O O
vaccine, O O O O
if O O O O
approved O O O O
for O O O O
use O O O O
in O O O O
patients, O O O O
could O O O O
prevent O O O O
deadly O O O O
infections O O O O
and O O O O
save O O O O
the O O O O
lives O O O O
of O O O O
thousands O O O O
of O O O O
patients O O O O
in O O O O
hospitals O O O O
worldwide O O O O
who O O O O
might O O O O
otherwise O O O O
contract O O O O
infections O O O O
and O O O O
die." O O O O
CARB-X O O O O
is O O O O
a O O O O
non-profit O O O O
organisation O O O O
led O O O O
by O O O O
Boston O O O O
University. O O O O
It O O O O
focuses O O O O
on O O O O
antibacterial O O O O
research O O O O
and O O O O
development O O O O
(R&D) O O O O
targeting O O O O
drug-resistant O O O O
bacteria. O O O O
The O O O O
organisation O O O O
receives O O O O
funding O O O O
from O O O O
the O O O O
US O O O O
Biomedical O O O O
Advanced O O O O
Research O O O O
and O O O O
Development O O O O
Authority O O O O
(BARDA). O O O O
CARB-X O O O O
has O O O O
committed O O O O
up O O O O
to O O O O
$500m O O O O
antibacterial O O O O
R&D O O O O
investment O O O O
over O O O O
2016-2021 O O O O
to O O O O
support O O O O
new O O O O
antibiotics, O O O O
vaccines, O O O O
diagnostics O O O O
and O O O O
other O O O O
products. O O O O
In O O O O
March, O O O O
[Germany's O O O O
Federal O O O O
Ministry O O O O
of O O O O
Education O O O O
and O O O O
Research O O O O
(BMBF) O O O O
signed O O O O
an O O O O
agreement O O O O
to O O O O
support O O O O
CARB-X](https://www.pharmaceutical-technology.com/news/german-carb-x-partnership/) O O O O
with O O O O
â‚¬39m O O O O
($43.25m) O O O O
over O O O O
four O O O O
years O O O O
